At a glance
- Originator Fujisawa
- Class Cardiotonics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 22 Aug 2002 Discontinued - Phase-II for Heart failure in Japan (unspecified route)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa